Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
155 hedge funds and large institutions have $1.57B invested in Aimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 30 closing their positions.
96% more call options, than puts
Call options by funds: $16.3M | Put options by funds: $8.33M
44% more capital invested
Capital invested by funds: $1.09B → $1.57B (+$480M)
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
6% more funds holding
Funds holding: 146 → 155 (+9)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$18.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13M |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$12M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$54.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$12.9M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$12.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.6M |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$10.2M |
AIMT Hedge Fund Activity: Q4 2019 in Review
155 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2019, worth a combined $1.57B — up 44% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AIMT positions and 30 closed out — a net gain of 11 holders — while 53 added to existing stakes and 37 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $18.1M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $54.6M sold.
- 155 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2019, up from 146 in Q3 2019.
- Funds reported $1.57B of Aimmune Therapeutics stock for Q4 2019, up 44% quarter-over-quarter.
- 41 funds opened new Aimmune Therapeutics positions in Q4 2019 and 30 closed out, a net change of +11 holders.
- The largest Aimmune Therapeutics buyer in Q4 2019 was Victory Capital Management, an estimated $18.1M added.
- The largest Aimmune Therapeutics seller in Q4 2019 was Foresite Capital Management II, an estimated $54.6M sold.
Based on aggregated 13F filings for Q4 2019.